Call End:
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Q2 2024 Earnings Conference Call
August 08, 2024, 08:30 AM ET

Company Participants

Michael Kalb - Chief Financial Officer
Richard Daly - President and Chief Executive Officer
Jeffrey Del Carmen - Chief Commercial Officer
Steven Miller - Chief Operating Officer and Chief Scientific Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald
Samantha Semenkow - Citibank
Jason Gerberry - Bank of America
Leland Gershall - Oppenheimer & Company
Joe Catanzaro - Piper Sandler

Operator

Greetings, and welcome to the Catalyst Pharmaceuticals' Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Michael Kalb, CFO. Thank you, Michael. You may begin.

Michael Kalb

Thank you. Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's second quarter 2024 financial results and business highlights. Richard Daly, President and CEO will be leading the call today, and Jeffrey Del Carmen, our Chief Commercial Officer, and I will also present. Additionally, Dr. Steven Miller, our Chief Operating Officer and $Scientific Officer will be available for the Q&A.

Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates, and projections, and are not guarantees of future performance. They involve risks, uncertainties, and assumptions that are difficult to predict and may not prove to be accurate. Actual results may vary from the expectations contained in our forward-looking statements.

These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings including the risk factors described in our 2023 annual report on Form 10-K filed with the SEC on February 28, 2024 and in our second quarter 2024 quarterly report on Form 10-Q which we filed yesterday, August 7, 2024 with the SEC.

At this time, I'll turn the call over to Rich.

Richard Daly

Thanks Mike, and thank you all for joining today's call. Today we'll review our second quarter 2024 corporate performance, provide an update on our regulatory and strategic growth initiatives, dive deeper into individual product performance, and conclude with a comprehensive overview of our financial results.